STAAR Surgical (NASDAQ:STAA) Receives Average Recommendation of "Hold" from Brokerages

STAAR Surgical (NASDAQ:STAA - Get Free Report) has been assigned a consensus rating of "Hold" from the ten analysts that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, eight have given a hold recommendation and one has given a buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $25.29.

A number of brokerages have recently weighed in on STAA. Jefferies Financial Group lowered shares of STAAR Surgical from a "buy" rating to a "hold" rating in a research note on Wednesday, February 12th. William Blair cut STAAR Surgical from an "outperform" rating to a "market perform" rating in a research note on Wednesday, February 12th. Needham & Company LLC reaffirmed a "hold" rating on shares of STAAR Surgical in a research note on Thursday, February 27th. StockNews.com lowered STAAR Surgical from a "hold" rating to a "sell" rating in a research report on Thursday, February 13th. Finally, Stifel Nicolaus reduced their target price on shares of STAAR Surgical from $38.00 to $20.00 and set a "buy" rating on the stock in a research report on Wednesday, February 12th.

STAAR Surgical Stock Performance

STAA stock traded up $0.05 on Friday, reaching $17.77. The company's stock had a trading volume of 880,160 shares, compared to its average volume of 765,994. The firm has a market cap of $876.51 million, a PE ratio of -43.34 and a beta of 0.66. The business has a fifty day simple moving average of $19.77 and a two-hundred day simple moving average of $25.52. STAAR Surgical has a 12-month low of $13.50 and a 12-month high of $52.68.

Remove Ads

Insider Activity

In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. acquired 8,221 shares of STAAR Surgical stock in a transaction that occurred on Thursday, January 16th. The stock was bought at an average cost of $21.50 per share, for a total transaction of $176,751.50. Following the acquisition, the insider now owns 10,878,007 shares of the company's stock, valued at $233,877,150.50. This represents a 0.08 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders have bought a total of 1,036,187 shares of company stock worth $17,239,548 over the last 90 days. 1.00% of the stock is currently owned by insiders.

Institutional Trading of STAAR Surgical

A number of institutional investors have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in STAAR Surgical by 3.9% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,123 shares of the medical instruments supplier's stock valued at $683,000 after purchasing an additional 1,044 shares during the period. Quarry LP purchased a new position in shares of STAAR Surgical in the 3rd quarter worth $50,000. MetLife Investment Management LLC grew its holdings in shares of STAAR Surgical by 6.3% in the fourth quarter. MetLife Investment Management LLC now owns 30,396 shares of the medical instruments supplier's stock worth $738,000 after acquiring an additional 1,796 shares during the period. Larson Financial Group LLC increased its position in STAAR Surgical by 78.3% during the third quarter. Larson Financial Group LLC now owns 4,863 shares of the medical instruments supplier's stock valued at $181,000 after acquiring an additional 2,135 shares during the last quarter. Finally, Bridgefront Capital LLC lifted its holdings in STAAR Surgical by 27.2% in the fourth quarter. Bridgefront Capital LLC now owns 10,792 shares of the medical instruments supplier's stock valued at $262,000 after acquiring an additional 2,306 shares during the period. Hedge funds and other institutional investors own 96.70% of the company's stock.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.